{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,22]],"date-time":"2024-06-22T13:17:15Z","timestamp":1719062235220},"reference-count":69,"publisher":"Spandidos Publications","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["biom rep"],"DOI":"10.3892\/br.2018.1101","type":"journal-article","created":{"date-parts":[[2018,5,22]],"date-time":"2018-05-22T09:13:01Z","timestamp":1526980381000},"source":"Crossref","is-referenced-by-count":1,"title":["Potential candidate treatment agents for targeting of cholangiocarcinoma identified by gene expression profile analysis"],"prefix":"10.3892","author":[{"given":"Suthipong","family":"Chujan","sequence":"first","affiliation":[{"name":"Applied Biological Sciences Program, Chulabhorn Graduate Institute, Chulabhorn Royal Academy, Bangkok 10210, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tawit","family":"Suriyo","sequence":"additional","affiliation":[{"name":"Laboratory of Pharmacology, Chulabhorn Research Institute, Bangkok 10210, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teerapat","family":"Ungtrakul","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Public Health, HRH Princess Chulabhorn College of Medical Science, Chulabhorn Royal Academy, Bangkok 10210, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yotsawat","family":"Pomyen","sequence":"additional","affiliation":[{"name":"Translational Research Unit, Chulabhorn Research Institute, Chulabhorn Royal Academy, Bangkok 10210, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jutamaad","family":"Satayavivad","sequence":"additional","affiliation":[{"name":"Laboratory of Pharmacology, Chulabhorn Research Institute, Bangkok 10210, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2018,5,22]]},"reference":[{"key":"key20200712190043_b1-br-0-0-1101","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1056\/NEJM199910283411807","article-title":"Biliary tract cancers","volume":"341","author":"de Groen","year":"1999","journal-title":"N Engl J Med"},{"key":"key20200712190043_b2-br-0-0-1101","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1053\/jhep.2002.34743","article-title":"Involvement of 85-kd cytosolic phospholipase A(2) and cyclooxygenase-2 in the proliferation of human cholangiocarcinoma cells","volume":"36","author":"Wu","year":"2002","journal-title":"Hepatology"},{"key":"key20200712190043_b3-br-0-0-1101","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/1471-2407-2-10","article-title":"Worldwide trends in mortality from biliary tract malignancies","volume":"2","author":"Patel","year":"2002","journal-title":"BMC Cancer"},{"key":"key20200712190043_b4-br-0-0-1101","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.jhep.2003.11.030","article-title":"Rising incidence of intrahepatic cholangiocarcinoma in the United States: A true increase?","volume":"40","author":"Shaib","year":"2004","journal-title":"J Hepatol"},{"key":"key20200712190043_b5-br-0-0-1101","first-page":"463","article-title":"Cholangiocarcinoma","volume":"224","author":"Nakeeb","year":"1996","journal-title":"A spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg"},{"key":"key20200712190043_b6-br-0-0-1101","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1053\/jhep.2001.25087","article-title":"Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States","volume":"33","author":"Patel","year":"2001","journal-title":"Hepatology"},{"key":"key20200712190043_b7-br-0-0-1101","doi-asserted-by":"publisher","first-page":"324","DOI":"10.21037\/jgo.2016.09.16","article-title":"Targeted therapy in biliary tract cancers-current limitations and potentials in the future","volume":"8","author":"Sahu","year":"2017","journal-title":"J Gastrointest Oncol"},{"key":"key20200712190043_b8-br-0-0-1101","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1016\/0016-5085(95)90650-9","article-title":"Ki-ras mutations and p53 protein expressions in intrahepatic cholangiocarcinomas: Relation to gross tumor morphology","volume":"109","author":"Ohashi","year":"1995","journal-title":"Gastroenterology"},{"key":"key20200712190043_b9-br-0-0-1101","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1046\/j.1365-2559.1999.00705.x","article-title":"Protein expression and genetic alterations of p53 and ras in intrahepatic cholangiocarcinoma","volume":"35","author":"Furubo","year":"1999","journal-title":"Histopathology"},{"key":"key20200712190043_b10-br-0-0-1101","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1136\/gut.52.5.706","article-title":"Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma","volume":"52","author":"Tannapfel","year":"2003","journal-title":"Gut"},{"key":"key20200712190043_b11-br-0-0-1101","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1172\/JCI27282","article-title":"Induction of intrahepatic cholangiocellular carcinoma by liver-specific disruption of Smad4 and Pten in mice","volume":"116","author":"Xu","year":"2006","journal-title":"J Clin Invest"},{"key":"key20200712190043_b12-br-0-0-1101","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1053\/jhep.2002.34435","article-title":"ERBB-2 overexpression and cyclooxygenase-2 up-regulation in human cholangiocarcinoma and risk conditions","volume":"36","author":"Endo","year":"2002","journal-title":"Hepatology"},{"key":"key20200712190043_b13-br-0-0-1101","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1046\/j.1365-2559.1998.00445.x","article-title":"Relationship between interleukin-6 and proliferation and differentiation in cholangiocarcinoma","volume":"33","author":"Sugawara","year":"1998","journal-title":"Histopathology"},{"key":"key20200712190043_b14-br-0-0-1101","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1056\/NEJMp1100548","article-title":"Early accelerated approval for highly targeted cancer drugs","volume":"364","author":"Chabner","year":"2011","journal-title":"N Engl J Med"},{"key":"key20200712190043_b15-br-0-0-1101","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1158\/1535-7163.299.3.3","article-title":"The cyclooxygenase-2 inhibitor celecoxib blocks phosphorylation of Akt and induces apoptosis in human cholangiocarcinoma cells","volume":"3","author":"Wu","year":"2004","journal-title":"Mol Cancer Ther"},{"key":"key20200712190043_b16-br-0-0-1101","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1111\/bcp.12641","article-title":"Statins are associated with a reduced risk of cholangiocarcinoma: A population-based case-control study","volume":"80","author":"Peng","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"key20200712190043_b17-br-0-0-1101","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1053\/j.gastro.2011.12.005","article-title":"Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors","volume":"142","author":"Andersen","year":"2012","journal-title":"Gastroenterology"},{"key":"key20200712190043_b18-br-0-0-1101","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/75556","article-title":"The Gene Ontology Consortium: Gene ontology: Tool for the unification of biology","volume":"25","author":"Ashburner","year":"2000","journal-title":"Nat Genet"},{"key":"key20200712190043_b19-br-0-0-1101","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/nar\/gkn923","article-title":"Bioinformatics enrichment tools: Paths toward the comprehensive functional analysis of large gene lists","volume":"37","author":"Huang","year":"2009","journal-title":"Nucleic Acids Res"},{"key":"key20200712190043_b20-br-0-0-1101","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/nar\/28.1.27","article-title":"KEGG: Kyoto encyclopedia of genes and genomes","volume":"28","author":"Kanehisa","year":"2000","journal-title":"Nucleic Acids Res"},{"key":"key20200712190043_b21-br-0-0-1101","doi-asserted-by":"publisher","first-page":"D561","DOI":"10.1093\/nar\/gkq973","article-title":"The STRING database in 2011: Functional interaction networks of proteins, globally integrated and scored","volume":"39","author":"Szklarczyk","year":"2011","journal-title":"Nucleic Acids Res"},{"key":"key20200712190043_b22-br-0-0-1101","doi-asserted-by":"publisher","first-page":"D433","DOI":"10.1093\/nar\/gki005","article-title":"STRING: Known and predicted protein-protein associations, integrated and transferred across organisms","volume":"33","author":"von Mering","year":"2005","journal-title":"Nucleic Acids Res"},{"key":"key20200712190043_b23-br-0-0-1101","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Cancer Genome Atlas Research Network: Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Kandoth","year":"2013","journal-title":"Nature"},{"key":"key20200712190043_b24-br-0-0-1101","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Sci Signal"},{"key":"key20200712190043_b25-br-0-0-1101","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov"},{"key":"key20200712190043_b26-br-0-0-1101","doi-asserted-by":"publisher","first-page":"3069","DOI":"10.1093\/bioinformatics\/btv313","article-title":"DSigDB: Drug signatures database for gene set analysis","volume":"31","author":"Yoo","year":"2015","journal-title":"Bioinformatics"},{"key":"key20200712190043_b27-br-0-0-1101","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1126\/science.1132939","article-title":"The Connectivity Map: Using gene-expression signatures to connect small molecules, genes, and disease","volume":"313","author":"Lamb","year":"2006","journal-title":"Science"},{"issue":"D1","key":"key20200712190043_b28-br-0-0-1101","doi-asserted-by":"publisher","first-page":"D1118","DOI":"10.1093\/nar\/gkt1129","article-title":"Therapeutic target database update 2014: A resource for targeted therapeutics","volume":"42","author":"Qin","year":"2014","journal-title":"Nucleic Acids Res"},{"key":"key20200712190043_b29-br-0-0-1101","doi-asserted-by":"publisher","first-page":"bat080","DOI":"10.1093\/database\/bat080","article-title":"A CTD-Pfizer collaboration: Manual curation of 88,000 scientific articles text mined for drug-disease and drug-phenotype interactions","volume":"2013","author":"Davis","year":"2013","journal-title":"Database (Oxford)"},{"key":"key20200712190043_b30-br-0-0-1101","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1002\/jhbp.68","article-title":"Cancer biomarker discovery for cholangiocarcinoma: The high-throughput approaches","volume":"21","author":"Silsirivanit","year":"2014","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"key20200712190043_b31-br-0-0-1101","doi-asserted-by":"publisher","first-page":"35874","DOI":"10.1038\/srep35874","article-title":"Tumour growth environment modulates Chk1 signalling pathways and Chk1 inhibitor sensitivity","volume":"6","author":"Massey","year":"2016","journal-title":"Sci Rep"},{"key":"key20200712190043_b32-br-0-0-1101","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/cgt.2016.64","article-title":"Identification of transcription factors (TFs) and targets involved in the cholangiocarcinoma (CCA) by integrated analysis","volume":"23","author":"Yang","year":"2016","journal-title":"Cancer Gene Ther"},{"key":"key20200712190043_b33-br-0-0-1101","first-page":"53","article-title":"Hypoxia enhances aggressiveness of cholangiocarcinoma cells","volume":"13","author":"Seubwai","year":"2012","journal-title":"Asian Pac J Cancer Prev"},{"key":"key20200712190043_b34-br-0-0-1101","doi-asserted-by":"publisher","first-page":"e1004135","DOI":"10.1371\/journal.pgen.1004135","article-title":"Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma","volume":"10","author":"Borad","year":"2014","journal-title":"PLoS Genet"},{"key":"key20200712190043_b35-br-0-0-1101","doi-asserted-by":"publisher","first-page":"3697","DOI":"10.7314\/APJCP.2015.16.9.3697","article-title":"High expression of matrix metalloproteinase-11 indicates poor prognosis in human cholangiocarcinoma","volume":"16","author":"Tongtawee","year":"2015","journal-title":"Asian Pac J Cancer Prev"},{"key":"key20200712190043_b36-br-0-0-1101","doi-asserted-by":"publisher","first-page":"580","DOI":"10.4172\/1948-5956.1000477","article-title":"Integrative analysis of transcriptome and microRNome profiles in cholangiocarcinoma","volume":"09","author":"Severino","year":"2017","journal-title":"J Cancer Sci Ther"},{"key":"key20200712190043_b37-br-0-0-1101","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1093\/gastro\/gou066","article-title":"Bile proteomics for differentiation of malignant from benign biliary strictures: A pilot study","volume":"3","author":"Navaneethan","year":"2015","journal-title":"Gastroenterol Rep (Oxf)"},{"key":"key20200712190043_b38-br-0-0-1101","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/cgt.2015.66","article-title":"Screening of potential biomarkers for cholangiocarcinoma by integrated analysis of microarray data sets","volume":"23","author":"Huang","year":"2016","journal-title":"Cancer Gene Ther"},{"key":"key20200712190043_b39-br-0-0-1101","first-page":"73","article-title":"The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer","volume-title":"Adv Cancer Res","author":"Smith","year":"2010"},{"key":"key20200712190043_b40-br-0-0-1101","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/S1535-6108(03)00110-7","article-title":"Chk1 and Chk2 kinases in checkpoint control and cancer","volume":"3","author":"Bartek","year":"2003","journal-title":"Cancer Cell"},{"key":"key20200712190043_b41-br-0-0-1101","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1038\/sj.bjc.6690699","article-title":"Detection of the pancreas-specific gene in the peripheral blood of patients with pancreatic carcinoma","volume":"81","author":"Kuroki","year":"1999","journal-title":"Br J Cancer"},{"key":"key20200712190043_b42-br-0-0-1101","doi-asserted-by":"publisher","first-page":"18669","DOI":"10.1038\/srep18669","article-title":"Genetic alterations in fatty acid transport and metabolism genes are associated with metastatic progression and poor prognosis of human cancers","volume":"6","author":"Nath","year":"2016","journal-title":"Sci Rep"},{"key":"key20200712190043_b43-br-0-0-1101","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1007\/s11434-016-1129-4","article-title":"Fatty acid metabolism and cancer development","volume":"61","author":"Chen","year":"2016","journal-title":"Sci Bull (Beijing)"},{"key":"key20200712190043_b44-br-0-0-1101","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1002\/biot.201100305","article-title":"Molecular signatures from omics data: From chaos to consensus","volume":"7","author":"Sung","year":"2012","journal-title":"Biotechnol J"},{"key":"key20200712190043_b45-br-0-0-1101","doi-asserted-by":"publisher","first-page":"23078","DOI":"10.1038\/srep23078","article-title":"Identification of potential drug targets in cancer signaling pathways using stochastic logical models","volume":"6","author":"Zhu","year":"2016","journal-title":"Sci Rep"},{"key":"key20200712190043_b46-br-0-0-1101","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1158\/1078-0432.CCR-06-2672","article-title":"Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma","volume":"13","author":"Mann","year":"2007","journal-title":"Clin Cancer Res"},{"key":"key20200712190043_b47-br-0-0-1101","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S0140-6736(10)60893-8","article-title":"Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: A proof-of-concept trial","volume":"376","author":"Audeh","year":"2010","journal-title":"Lancet"},{"key":"key20200712190043_b48-br-0-0-1101","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1517\/14656566.2012.689130","article-title":"Sunitinib malate for the treatment of renal cell carcinoma","volume":"13","author":"Wood","year":"2012","journal-title":"Expert Opin Pharmacother"},{"key":"key20200712190043_b49-br-0-0-1101","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.bbrc.2010.07.092","article-title":"RAF protein-serine\/threonine kinases: Structure and regulation","volume":"399","author":"Roskoski","year":"2010","journal-title":"Biochem Biophys Res Commun"},{"key":"key20200712190043_b50-br-0-0-1101","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3892\/ol.2014.2637","article-title":"Raf kinase inhibitor protein inhibits cholangiocarcinoma cell metastasis by downregulating matrix metalloproteinase 9 and upregulating tissue inhibitor of metalloproteinase 4 expression","volume":"9","author":"Ma","year":"2015","journal-title":"Oncol Lett"},{"key":"key20200712190043_b51-br-0-0-1101","doi-asserted-by":"publisher","first-page":"910","DOI":"10.4254\/wjh.v7.i6.910","article-title":"Disease control with sunitinib in advanced intrahepatic cholangiocarcinoma resistant to gemcitabine-oxaliplatin chemotherapy","volume":"7","author":"Dreyer","year":"2015","journal-title":"World J Hepatol"},{"key":"key20200712190043_b52-br-0-0-1101","first-page":"155","article-title":"Chemotherapy outcomes for the treatment of unresectable intrahepatic and hilar cholangiocarcinoma: A retrospective analysis","volume":"4","author":"Eckmann","year":"2011","journal-title":"Gastrointest Cancer Res"},{"key":"key20200712190043_b53-br-0-0-1101","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"ABC-02 Trial Investigators: Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J Med"},{"key":"key20200712190043_b54-br-0-0-1101","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1007\/s11864-015-0366-0","article-title":"Targeted therapy in biliary tract cancers","volume":"16","author":"Merla","year":"2015","journal-title":"Curr Treat Options Oncol"},{"key":"key20200712190043_b55-br-0-0-1101","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1245\/s10434-015-5046-6","article-title":"Cholangiocarcinoma heterogeneity revealed by multigene mutational profiling: Clinical and prognostic relevance in surgically resected patients","volume":"23","author":"Ruzzenente","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"key20200712190043_b56-br-0-0-1101","doi-asserted-by":"publisher","first-page":"14744","DOI":"10.18632\/oncotarget.4539","article-title":"Genetic heterogeneity in cholangiocarcinoma: A major challenge for targeted therapies","volume":"6","author":"Brandi","year":"2015","journal-title":"Oncotarget"},{"key":"key20200712190043_b57-br-0-0-1101","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.3892\/ol.2017.5563","article-title":"Repurposing cimetidine for cholangiocarcinoma: Antitumor effects in vitro and in vivo","volume":"13","author":"Dana","year":"2017","journal-title":"Oncol Lett"},{"key":"key20200712190043_b58-br-0-0-1101","doi-asserted-by":"publisher","first-page":"374593","DOI":"10.1155\/2013\/374593","article-title":"Sodium valproate inhibits the growth of human cholangiocarcinoma in vitro and in vivo","volume":"2013","author":"Wang","year":"2013","journal-title":"Gastroenterol Res Pract"},{"key":"key20200712190043_b59-br-0-0-1101","first-page":"73","article-title":"Metabolic characteristics distinguishing intrahepatic cholangiocarcinoma: A negative pilot study of (18)F-fluorocholine PET\/CT clarified by transcriptomic analysis","volume":"6","author":"Kwee","year":"2016","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"key20200712190043_b60-br-0-0-1101","doi-asserted-by":"crossref","first-page":"23857","DOI":"10.18632\/oncotarget.4408","article-title":"Lovastatin overcomes gefitinib resistance through TNF-\u03b1 signaling in human cholangiocarcinomas with different LKB1 statuses in vitro and in vivo","volume":"6","author":"Yang","year":"2015","journal-title":"Oncotarget"},{"key":"key20200712190043_b61-br-0-0-1101","doi-asserted-by":"crossref","first-page":"362","DOI":"10.18632\/oncotarget.6238","article-title":"Integrin \u03b23 and LKB1 are independently involved in the inhibition of proliferation by lovastatin in human intrahepatic cholangiocarcinoma","volume":"7","author":"Yang","year":"2016","journal-title":"Oncotarget"},{"key":"key20200712190043_b62-br-0-0-1101","first-page":"4922","article-title":"The effects of lovastatin on the morphology, cell viability and differentiation of stem cells derived from gingiva","volume":"28","author":"Kim","year":"2017","journal-title":"Biomed Res (Aligarh)"},{"key":"key20200712190043_b63-br-0-0-1101","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1023\/A:1008204911774","article-title":"A phase II study of oral clofazimine in unresectable and metastatic hepatocellular carcinoma","volume":"9","author":"Ruff","year":"1998","journal-title":"Ann Oncol"},{"key":"key20200712190043_b64-br-0-0-1101","doi-asserted-by":"publisher","first-page":"93","DOI":"10.4103\/2141-9248.153609","article-title":"Anticancer effect of antimalarial artemisinin compounds","volume":"5","author":"Das","year":"2015","journal-title":"Ann Med Health Sci Res"},{"key":"key20200712190043_b65-br-0-0-1101","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1136\/gut.48.1.80","article-title":"Aberrant cyclooxygenase isozyme expression in human intrahepatic cholangiocarcinoma","volume":"48","author":"Chariyalertsak","year":"2001","journal-title":"Gut"},{"key":"key20200712190043_b66-br-0-0-1101","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/1479-5876-6-27","article-title":"Molecular analysis of the effects of piroxicam and cisplatin on mesothelioma cells growth and viability","volume":"6","author":"Verdina","year":"2008","journal-title":"J Transl Med"},{"key":"key20200712190043_b67-br-0-0-1101","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.ijpharm.2011.10.057","article-title":"Anti-tumor activity of all-trans retinoic acid-incorporated glycol chitosan nanoparticles against HuCC-T1 human cholangiocarcinoma cells","volume":"422","author":"Chung","year":"2012","journal-title":"Int J Pharm"},{"key":"key20200712190043_b68-br-0-0-1101","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1158\/1055-9965.EPI-15-0137","article-title":"Coffee consumption and risk of hepatocellular carcinoma and intrahepatic cholangiocarcinoma by sex: The liver cancer pooling project","volume":"24","author":"Petrick","year":"2015","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"key20200712190043_b69-br-0-0-1101","doi-asserted-by":"publisher","first-page":"e013739","DOI":"10.1136\/bmjopen-2016-013739","article-title":"Coffee, including caffeinated and decaffeinated coffee, and the risk of hepatocellular carcinoma: A systematic review and dose-response meta-analysis","volume":"7","author":"Kennedy","year":"2017","journal-title":"BMJ Open"}],"container-title":["Biomedical Reports"],"original-title":[],"deposited":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T00:09:51Z","timestamp":1661299791000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/br.2018.1101"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,22]]},"references-count":69,"URL":"https:\/\/doi.org\/10.3892\/br.2018.1101","relation":{},"ISSN":["2049-9434","2049-9442"],"issn-type":[{"value":"2049-9434","type":"print"},{"value":"2049-9442","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,22]]}}}